Telix Pharmaceuticals Limited (ASX: TLX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 4.88B |
| Revenue (ttm) | 502.55M |
| Net Income (ttm) | 5.21M |
| Shares Out | 323.73M |
| EPS (ttm) | 0.02 |
| PE Ratio | 740.00 |
| Forward PE | 21.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,741 |
| Open | 15.39 |
| Previous Close | 14.80 |
| Day's Range | 14.54 - 15.40 |
| 52-Week Range | 8.20 - 15.60 |
| Beta | 2.31 |
| Analysts | n/a |
| Price Target | 15.29 (+3.59%) |
| Earnings Date | Feb 22, 2024 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagno... [Read more]
Financial Performance
Financial StatementsNews
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
MELBOURNE, Australia, May 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has filed a registration statement on Form F-1 (Registration...
Telix Pharmaceuticals reports Q1 results
Telix Pharmaceuticals reports Q1 revenue of $114.9M, a YoY increase of 18.3%.
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhance...
Telix Pharmaceuticals Ltd Grand Pharma Investor Webinar Transcript
Telix Pharmaceuticals Ltd Grand Pharma Investor Webinar Transcript
Telix Pharmaceuticals Limited (TLPPF) Q4 2023 Earnings Call Transcript
Telix Pharmaceuticals GAAP EPS of A$1.61, revenue of A$502.55M
Telix Announces Planned Registered Public Offering and Listing in the United States
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of A...
QSAM Biosciences signs term sheet to be acquired by Telix Pharmaceuticals
QSAM Biosciences has signed a non-binding term sheet to be acquired by Telix Pharmaceuticals, with a collaboration fee of $2 million.
Telix Pharmaceuticals reports Q3 results
Telix Pharmaceuticals reports fourth consecutive quarter of positive operating cash flow, with Q3 revenue of $133.6M and a closing cash balance of $137.4M.
Telix reports fourth consecutive quarter of positive operating cash flow
MELBOURNE, Australia , Oct. 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Re...
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
MELBOURNE, Australia , Aug. 23, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2023. All figure...
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Aug. 10, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III r...
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
MELBOURNE, Australia , Aug. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company's...
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
MELBOURNE, Australia , July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Re...
Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter
MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
MELBOURNE, Australia, April 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an ant...
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
INDIANAPOLIS , March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supp...
Telix Reports Fourth Quarter 2022 Financial Results
MELBOURNE, Australia , Jan. 17, 2023 /PRNewswire/ -- 18 January 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accomp...
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
MELBOURNE, Australia , Jan. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9 ...
Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercial...
Telix Reports Third Quarter 2022 Financial Results
MELBOURNE, Australia , Oct. 19, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia , July 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities...
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS , April 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement wit...
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with G...
FDA Approves Telix's Prostate Cancer Imaging Product, Illuccix®
MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development of ...